# Epizyme

**Canonical:** https://apis.io/providers/epizyme/  
**Website:** https://www.epizyme.com  
**APIs profiled:** 0

Epizyme, Inc. was a Cambridge, Massachusetts biopharmaceutical company developing epigenetic therapies for cancer and other diseases. Its lead product, TAZVERIK (tazemetostat), is an oral EZH2 inhibitor approved by the FDA for epithelioid sarcoma and relapsed/refractory follicular lymphoma. Epizyme was acquired by Ipsen in 2022. It was added to the API Evangelist network as a stub via the kleiner-perkins venture portfolio; the company operates no public developer program, API, or documentation surface, and its former corporate website (epizyme.com) is no longer serving a web presence though the domain remains registered and mail-active.

## Kin Score — 3.3 / 100 (minimal)

Scored 2026-08-21 under rubric 0.12.0. Trend: flat (+0.0 from 3.3).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Epizyme Domain Security** — DMARC

## Tags

Company, Healthcare, Biotechnology, Pharmaceuticals, Oncology, Epigenetics

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/epizyme/). Scores are computed from the provider's own public artifacts under a published rubric.